Hypertension: Old Foe 🥊, Novel Therapies 🛡️, Brighter Outcomes 🌈

🚨 Hypertension remains the world's #1 killer — yet fewer than 1 in 4 patients achieve control.   💊 Exciting innovations are reshaping the field: ✔️ Aprocitentan (endothelin receptor antagonist) – first new class in decades ✔️ siRNA (zilebesiran) – 6-monthly dosing, tackling adherence ✔️ Aldosterone synthase inhibitors – overcoming "aldosterone escape" ✔️ Non-steroidal MRAs & neprilysin inhibitors – precision targeting with broader benefits ✔️ Single-pill & quadpill combos – simplifying therapy, boosting adherence   🌍 Together, these therapies + smarter management could transform outcomes in resistant and uncontrolled hypertension.